TetraGenetics and ImmunoPrecise extend collaboration by signing multi-target service agreement for the Discovery of Therapeutic Antibodies
VICTORIA, April 9th, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce the extension of its collaboration with TetraGenetics, a biopharmaceutical company developing novel therapeutics for autoimmune diseases. The alliance is focused on the discovery of novel human monoclonal antibodies against three undisclosed therapeutically-relevant ion-channels.
“We are pleased to work with ImmunoPrecise, utilizing their customized phage library technology,” said Douglas Kahn, TetraGenetics Chairman and CEO. “We expect our unique ion channel screening tools to enable deep mining of ImmunoPrecise’s patient library repertoire to identify rare and functional monoclonal antibodies that we can develop as therapeutics” This multi-target service agreement is the result of a successful research collaboration, utilizing ModiQuests’ natural human phage library repertoire combined with TetraGenetics’ unique ion channel screening tools, in which a multitude of potent pre-clinical lead antibodies were discovered.
“TetraGenetics’ unique capability to generate high concentrations of difficult-to-produce ion channel proteins caught our attention,” said Jennifer Bath, CEO of ImmunoPrecise. “TetraGenetics will provide us with unique screening formulations which should be highly effective for antibody discovery with our proprietary libraries. We’re look forward to a close collaboration with TetraGenetics, and are excited by the potential of combining the two unique technologies.”
Ted Clark, Chief Scientific Officer and Founder of TetraGenetics added, “Combining TetraGenetics and ImmunoPrecise proprietary technologies is likely to lead to the discovery of novel therapeutic antibodies to previously intractable targets for a variety of unmet medical needs. We’re eager to expand this collaboration”
TetraGenetics is focused on the discovery and development of first-in-class biologic medicines for autoimmune diseases, oncology and pain. The company has the leading drug discovery platform (TetraExpress™) for identifying antibodies targeting ion channels and other transmembrane proteins. TetraGenetics establishes collaborative partnerships with major biotech companies for antibody drug discovery and is also actively developing its own proprietary drug pipeline. For more information, please visit: www.tetragenetics.com.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.
ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, in collaboration with its wholly-owned subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht, and ModiQuest Research, Oss, both in the Netherlands. The Company operates globally to offer antibody services from target analysis to pre-clinical studies.
The services offered to clients include antibody discovery against a broad spectrum of antigens, including challenging targets. Amongst these services, the Company offers hybridoma production, B-cell services, and a variety of phage display platforms. The Company also provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’s annual management discussion and analysis for the fiscal year ended April 30, 2018 which can be accessed at www.sedar.com. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.